ClinicalTrials.gg
RecruitingNCT07599150ICAREUpdated Sep 23, 2026

Intracranial CArtography of Cortical Contribution to Respiratory Load Compensation in Epilepsy

An interventional study of SEEG monitoring and Comprehensive respiratory monitoring in Epilepsy and SUDEP, sponsored by Hospices Civils de Lyon. Recruiting at 1 site in France. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-09-23.

Primary conditionSudden Unexpected Death in EpilepsyRegistry: EpilepsyReclassifiedWhy we changed it
Registry
Epilepsy — the first condition term the registry derived for this study.
ClinicalTrials.gg
Sudden Unexpected Death in Epilepsy
Why
  1. The study's listed conditions name Sudden Unexpected Death in Epilepsy, a narrower term within Epilepsy.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Hospices Civils de Lyon · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Started Sep 2026; still recruiting 1 month later.
Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Study summary

30% of patients with epilepsy suffer from drug-resistant seizures and have a greater risk of premature mortality than the general population. Among all causes of death, the most frequent is SUDEP, for sudden and unexpected death in epilepsy patients. SUDEP typically occurs after a nocturnal seizure, and primarily results from a postictal central respiratory dysfunction in patients with generalized convulsive seizure (GCS), suggesting the critical role of seizure-related impairment of breathing control, and underscoring the importance of monitoring and preventive interventions during the post-ictal phase. Most of patients with drug-resistant seizures demonstrate transient peri-ictal apnea and hypoxemia especially in the aftermath of a GCS. Experimental and clinical data suggest that most SUDEP primarily result from a fatal seizure-related respiratory arrest 5. Apnea was the primary cause of death in several epilepsy models. In patients whose SUDEP had occurred during long-term video-EEG monitoring, we observed fatal postictal central apnea after a nocturnal GCS in all SUDEP. Accordingly, it is currently hypothesized that in a subgroup of patients, repetition of seizures may contribute to chronic alteration of respiratory regulation which may increase the risk of fatal postictal central respiratory arrest.

Central regulation of autonomic function is ensured by the so-called Central Autonomic Network (CAN), which anatomy in humans has primarily been investigated in neuroimaging studies or using intraEEG (iEEG) data in patients with drug-resistant focal epilepsy undergoing presurgical evaluation with intracerebral electrodes. Central regulation of breathing primarily rely on brainstem, especially the preBötzinger complex for rhythm generation and the retrotrapezoid nucleus and dorsal raphe for chemoreception, especially ventilatory response to hypercapnia. However, through an intricated structures connecting these regions, this respiratory signal projects to a network of cortical and subcortical regions mainly including the limbic and sensorimotor cortical areas. Studies in patients undergoing iEEG reinforced the role of limbic and paralimbic structures, with transient central apnea elicited by direct electrical stimulation of amygdala, hippocampus, anterior parahippocampal, and antero-mesial fusiform gyri. However, our group also reported transient hypoxemia could be elicited by cortical direct electrical stimulation outside the temporo-limbic structures, most commonly after stimulation of the perisylvian cortex. Importantly, our group recently showed that involvement of this perisylvian cortex in the epileptogenic zone is a strong risk factor of SUDEP, reinforcing the importance of further studying its integration in the cortical control of respiration.

The involvement of cortical control of ventilation is particularly important to ensure expiratory load compensation, a typical situation after GCS, which is associated with airway obstruction, especially when the face is positioned into the pillow. This cortical component of the physiological response to experimental expiratory loads was investigated in healthy subjects through the study of EEG activity during an expiratory load compensation protocol. Accordingly, EEGs were processed by ensemble averaging expiratory time-locked segments and examined for pre-expiratory EEG potentials, defined as a slow negative shift from the baseline signal preceding expiration, and suggestive of cortical preparation of expiration. Expiratory load compensation was associated with EEG premotor potential presumably involving the supplementary motor area. However, because of the limited spatial resolution of scalp EEG, the organization of cortical neural sources involved in this expiratory load compensation or during response to hypercapnia, especially the interaction between the premotor cortex, the sensorimotor cortical areas and the perisylvian cortex is unknown.

02

Conditions studied

  • Epilepsy
  • SUDEP

Browse trials for

Keywords

  • Epilepsy
  • SUDEP
  • respiratory challenges
  • evoked potentials
03

In context

Sudden Unexpected Death in Epilepsy Reclassified

23 studies on the registry are indexed under Sudden Unexpected Death in Epilepsy; 11 are open to participants now.

This study's planned enrollment of 20 is below the median of 35 across 12 interventional studies indexed under Sudden Unexpected Death in Epilepsy.

Browse Sudden Unexpected Death in Epilepsy studies →

Lead sponsor

Hospices Civils de Lyon is the lead sponsor of 1,866 studies on the registry; 448 are open to participants now.

Compared within Sudden Unexpected Death in Epilepsy, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Epilepsy. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written obtained from study subject and ability for study subject to comply with the requirements of the study
  2. Aged 18 to 55 years old
  3. Diagnosis of drug-resistant focal epilepsy, as defined by the International League Against Epilepsy 20
  4. Patients undergoing SEEG as part of presurgical evaluation
  5. At least one SEEG electrode localized in the perisylvian cortex
  6. At least one SEEG electrode localized in the premotor cortex

Exclusion criteria

Exclusion Criteria:

1. Ongoing or chronic respiratory and/or cardiac insufficiency and/or ischemic cardiac disease 2. History of stroke in the last 5 years 3. Intracranial hypertension related to space-occupying lesion in the brain 4. Pregnant, parturient, or breastfeeding women 5. Individuals receiving psychiatric care 6. Individuals deprived of their liberty by judicial or administrative decision 7. Adults subject to legal protection measures (guardianship, curatorship) 8. Individuals not affiliated with a social security scheme or beneficiaries of a similar scheme

-

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Patients with drug-resistant epilepsy

    Patients with drug-resistant focal epilepsy, as defined by the International League Against Epilepsy, who undergo SEEG as part of presurgical evaluation of epilepsy. In addition to SEEG monitoring, the following procedures will be carried out as part of the research: * Comprehensive respiratory monitoring * Cardio-respiratory monitoring * Expiratory load compensation * Hypercapnic challenge * Questionnaires completion.

    Procedure: SEEG monitoring · Procedure: Comprehensive respiratory monitoring · Procedure: Cardio-respiratory monitoring · Procedure: Expiratory load compensation · Procedure: Hypercapnic challenge · Other: Questionnaires

Interventions

  • ProcedureSEEG monitoring

    Patients will be recruited among adult patients suffering from drug-resistant focal epilepsy who undergo SEEG monitoring at the Epilepsy Department of the Neurological Hospital. The study will be offered to patients during the hospitalization.

  • ProcedureComprehensive respiratory monitoring

    In addition to SEEG monitoring, all participants will undergo comprehensive respiratory monitoring in order to collect respiratory data (tidal volume, VE, and respiratory rate) and gas exchange (PETO2 and PETCO2).

  • ProcedureCardio-respiratory monitoring

    In addition to SEEG channels, cardio-respiratory monitoring consisting of pulse oximetry, respiratory efforts (thoracic and abdominal) and EKG recordings will be performed.

  • ProcedureExpiratory load compensation

    Expiratory load compensation will be assessed in the patient's room in the epilepsy monitoring unit. Patients will breathe through a facemask connected in series to a bidirectional pneumotach and a three-way T-shaped valve. The second port on the three-way valve will be open to room air, and third port will be connected to a CE-marked PEEP valve (PEEP 20 valve, Ambu A/S Denmark) allowing to adjust airflow resistance during expiration from 0.15-2.0 kPa (1.5-20 cmH2O). Respired air will be continuously sampled at the mouth and analyzed for fractional concentrations of O2 and CO2.

  • ProcedureHypercapnic challenge

    The patient breathes through the mouth, using a mouthpiece and a nose clip, through a device fitted with a hermetically sealed bag that measures the various parameters of his/her breathing. At the start of the test, the patient breathes ambient air and his or her breathing is measured. Then, after a few minutes, the patient is connected to the bag, breathing in a closed circuit. This causes a gradual increase in carbon dioxide (CO2) in the inspired air. During this time, breathing parameters will be measured and gas exchanges studied with each breath. The test is stopped when the end-tidal carbon dioxide pressure (PetCO2) reaches 60 mm Hg, or in the event of intolerance.

  • OtherQuestionnaires

    Caffeine intake Self-report the degree of "breathlessness" during Expiratory load compensation using a visual analogue scale Self-report the degree of "breathlessness

06

What researchers measure

Primary outcomes

  1. Cortical localization of pre-expiratory potentials (via SEEG) during HETL (20 cmH₂O) in drug-resistant epilepsy

    Localization of SEEG contacts will use the anatomical MRI images performed in clinical routine. Pre-expiratory potentials are defined as a slow negative shift from the baseline signal starting between 2 and 0.5 s before the onset of expiration. Both visual and statistical analyses will be used to conclude on the presence of significant pre-expiratory potentials over each recording contact, using the same approach as the one our group used in the past in another physiological paradigm.

    Time frame: Through study completion, an average of 1 year

Secondary outcomes

  1. dentification of cortical SEEG contacts showing pre-expiratory potentials under 10 cmH₂O low expiratory threshold load (LETL) in drug-resistant epilepsy

    Will use the same criteria for localization of SEEG contacts and definition of pre-expiratory potentials as for the primary outcome measure.

    Time frame: Through study completion, an average of 1 year

  2. Cortical localization of SEEG contacts exhibiting pre-expiratory potentials during a hypercapnic challenge (HyperCO₂) in patients with drug-resistant epilepsy.

    Will use the same criteria for localization of SEEG contacts and definition of pre-expiratory potentials as for the primary outcome measure.

    Time frame: Through study completion, an average of 1 year

  3. Latency (ms) of the pre-expiratory potentials in each condition (HETL, LETL, HyperCO2)

    Time frame: Through study completion, an average of 1 year

  4. Value of hypercapnic ventilatory response (HCVR)* in each condition (HETL, LETL, HyperCO2)

    HCVR measures the increase in minute ventilation (VE) induced by an increase of PETCO2 and is a marker of central chemoreception

    Time frame: Through study completion, an average of 1 year

  5. Number of focal to bilateral tonic-clonic seizures during the 18 months preceding the SEEG

    SUDEP typically occurs after a nocturnal seizure , and primarily results from a postictal central respiratory dysfunction in patients with generalized convulsive seizure (GCS) , suggesting the critical role of seizure-related impairment of breathing control, and underscoring the importance of monitoring and preventive interventions during the post-ictal phase.

    Time frame: Inclusion visit

  6. Localization of the SEEG contacts included in the epileptogenic zone (EZ)

    The EZ corresponds to cortical regions that directly contribute by their abnormal synchronization to seizure initiation and which surgical removal would be required to result in seizure freedom. Its identification, which is the main medical of SEEG monitoring for presurgical evaluation, combines the analysis of all data collected during the SEEG (inter-ictal, seizures and direct electrical stimulations).

    Time frame: Inclusion visit

  7. Current and past mean daily intake of caffeine (mg/day)

    Current usual caffeine intake and the one over the last ten years will be assessed by a validated self-survey filled-in at home by the patient and, if needed, the help of the caregiver filled between the inclusion visit and the hospitalization.

    Time frame: Inclusion visit

  8. Respiratory discomfort of the experiment during each condition (HETL, LETL, HyperCO2)

    The degree of "respiratory discomfort" will be self-assessed by the subjects on a visual analog scale (VAS) . The subjects were asked to set the cursor on a 10-cm horizontal line, between the descriptions "no respiratory discomfort" on the left and "intolerable respiratory discomfort on the right.

    Time frame: Immediately after the respiratory challenges.

07

Study locations

1 of 1 sites recruiting
  • Service de Neurologie Fonctionne et d'Epileptologie Hôpital Neurologique Pierre WERTHEIMER
    Bron, Rhone 69500, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2026 (actual). Primary completion is estimated for Sep 2028, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2026
First posted
May 20, 2026
StartActual
Sep 17, 2026
Primary completionEst.
Sep 17, 2028
CompletionEst.
Sep 17, 2028
Last update
Sep 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07599150
Responsible party
Sponsor
First posted
May 20, 2026
Start date
Sep 17, 2026
Primary completion
Sep 17, 2028 (estimated)
Completion
Sep 17, 2028 (estimated)
Last update
Sep 23, 2026

Study contacts

Sylvain RHEIMS, Pr
Contact
sylvain.rheims@chu-lyon.fr
04 72 35 70 44 ext. +33
Mathilde GIRAUDON
Contact
camille.giraudon@chu-lyon.fr
04 26 73 94 38 ext. +33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion